Purchase this article with an account.
J.-J. Gicquel, J.-L. Bourges, J.-G. Bonneric, R. A. Bejjani, M. Langman, G. Renard, P. Dighiero; Topical Cyclosporine a 2% in Patients With Severe Ocular Rosacea After Penetrating Keratoplasty: A 3 Years Follow-Up. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4274.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate cyclosporine A (CsA) 2% eye-drops in the prevention of acute rejection after penetrating keratoplasty (PKP) in patients with severe ocular rosacea.
IRB approval (Poitiers School of Medicine) was given an Informed Consent was obtained from all patients according to French Regulations. 35 patients with severe Rosacea that underwent a PKP from 2000 to 2003 for pseudophakic bullous keratopathy were topically treated with CsA. The patient’s charts, the level of rejection risk, the IOP and the graft outcome were analyzed.
No systemic effect was detected. 21 rejections developed after a median of 18.5 months. Ten rejections under CsA treatment were reversible.
CsA 2% eye-drops are not an effective treatment in the prevention of acute rejection in patients with severe ocular rosacea.
This PDF is available to Subscribers Only